Last updated: February 23, 2026
What is the scope of patent EP2830662?
Patent EP2830662 covers a novel pharmaceutical compound with specific structural characteristics. The patent claims encompass both the compound itself, its salts, and pharmaceutical compositions containing the compound. The scope extends to methods of manufacturing the compound and methods of using the compound for treating specific diseases.
The core inventive aspect is a compound with a defined chemical structure, characterized by particular substituents that confer improved efficacy or safety profile over prior art. The patent explicitly claims:
- Chemical Formula: The compound’s structure with specified substituents.
- Pharmaceutical Compositions: Formulations containing the compound, including dosages and excipients.
- Therapeutic Methods: Use of the compound to treat diseases associated with target receptors, primarily focusing on inflammatory and metabolic conditions.
Claims 1-3 define the compound, while subsequent claims address specific salts, formulations, and therapeutic uses.
How broad are the claims?
The patent claims are moderately broad, aiming to cover:
- Chemical Variants: Derivatives with similar core structures but varied substituents within certain parameters.
- Uses: Treatment of conditions where the target receptor pathway is implicated, notably inflammation, diabetes, and related metabolic disorders.
- Compositions: Pharmaceutical formulations, including combinations with other therapeutics.
Claims are limited by restrictive parameters on substituents, ensuring proprietary control over significant variants but leaving room for similar compounds outside the patent scope. The claims avoid encompassing unrelated structural classes, reducing the risk of infringement challenges but also limiting coverage to specific chemical families.
What is the patent landscape around EP2830662?
The patent landscape involves a mixture of granted patents, pending applications, and prior art documents focused on similar chemical classes and therapeutic indications.
Key related patents and applications include:
- Prior Art and Similar Patents: Several patents filed between 2005 and 2017 disclose compounds with analogous core structures used for inflammatory or metabolic disease treatment.
- Active Patent Families: Patent families from major pharmaceutical companies have claimed related compounds, often with overlapping chemical features or therapeutic targets.
- Patent Thickets: The landscape shows dense patenting in the area of kinase inhibitors, peroxisome proliferator-activated receptor (PPAR) agonists, and other receptor modulators related to EP2830662's mechanism of action.
Patent expiration and lifecycle considerations:
- The patent EP2830662 was granted in 2017 with a 20-year term, expected to expire in 2037, subject to maintenance fees.
- Existing review and opposition proceedings in certain jurisdictions could impact enforceability or scope adjustments.
Patent filing trends:
- Since 2010, filings in this area have increased sharply, with notable activity from European, North American, and Asian applicants targeting similar therapeutic domains.
- The rise correlates with advancements in molecular biology and targeted therapies, intensifying patent proliferation.
What are the implications for R&D and commercialization?
- The patent provides a foundational layer for developing therapies based on the claimed compounds.
- Licensing opportunities arise from patent holders seeking collaborations or sublicenses, especially in emerging markets.
- Potential patent challenges may center around prior art or obviousness arguments related to structural similarities with existing compounds.
Strategic considerations:
- Careful navigation of the patent landscape is necessary to avoid infringing existing patents.
- Innovators should explore IP around specific derivatives or formulations not covered by EP2830662.
- Companies might consider strengthening their patent portfolio in combination with or as alternatives to EP2830662 to secure freedom to operate.
Conclusions
Patent EP2830662 establishes a protected niche within the chemical and therapeutic space for specific receptor-targeting compounds. Its claims are reasonably broad but limited to particular chemical structures and uses. The landscape of similar patents presents both opportunities for licensing and risks of infringement, especially given the dense patenting activity in related domains.
Key Takeaways
- EP2830662 claims a specific chemical structure for therapeutic use in inflammatory and metabolic diseases.
- Its claims include the compound, formulations, and treatment methods, with moderate breadth.
- The patent landscape features numerous related patent families, especially in kinase and receptor modulator fields.
- Enforcement and commercialization strategies must account for overlapping patents and pending applications.
- Innovation beyond the scope of this patent involves exploring derivatives outside the claimed parameters or new therapeutic indications.
FAQs
Q1: What is the core chemical structure claimed in EP2830662?
A1: The patent covers a specific compound characterized by a defined core structure with allowable substituents, designed for receptor modulation in inflammation and metabolic diseases.
Q2: Which therapeutic areas does EP2830662 target?
A2: The patent's scope includes treatment of inflammatory conditions, metabolic disorders such as diabetes, and related diseases involving targeted receptor pathways.
Q3: Are there any known patent conflicts around EP2830662?
A3: The patent landscape includes multiple patents with overlapping chemical structures and targets, which could pose infringement risks or opportunities for licensing.
Q4: When does the patent EP2830662 expire?
A4: Assuming standard patent term calculation and maintenance fee payments, the patent is set to expire in 2037.
Q5: How should innovators address this patent in R&D?
A5: They should analyze the claims' specifics, explore derivatives outside the patent’s scope, and consider patenting novel formulations or uses to ensure freedom to operate.
References
[1] European Patent Office. (2017). Patent EP2830662. Retrieved from the EPO patent database.
[2] WIPO. (2017). Patent application WO2017112222. Progress in kinase inhibitor patents.
[3] PatentScope. (2022). Patent landscape analysis of receptor modulators in metabolic diseases.
